Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18078250 | 1.00 | CTSL (0.51) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL18078251 | 0.92 | TRPM8 (0.52) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL7923876 | 0.91 | CTSL (0.49) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL18078255 | 0.89 | CTSL (0.50) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL1132567 | 0.87 | CTSL (0.56) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL10421483 | 0.87 | CTSL (0.56) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL1132569 | 0.87 | CTSL (0.56) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL11573515 | 0.87 | CTSL (0.56) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL18078256 | 0.85 | CTSL (0.47) | CTSLCTSSCTSBMEN1LMNA | |
| SCHEMBL11636828 | 0.84 | CTSL (0.53) | CTSLCTSSCYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802946-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9593145-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9512133-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160115197-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2016-04-28 | — | — | US | disclosed |
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2331571-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | UNIV NORTHWESTERN (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9101612-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011100585-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | MOSKAL JOSEPH (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2010033757-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSL 4016/4885CTSS 4517/4885CTSB 4118/4885 |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | GRIN2A, GRIN1, GRIN3A | CTSL 4593/4885CTSS 4529/4885CTSB 4297/4885 |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSL 4016/4885CTSS 4517/4885CTSB 4118/4885 |
| US-20160115197-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2A, GRIN1, GRIN3A | CTSL 4593/4885CTSS 4529/4885CTSB 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.